145 related articles for article (PubMed ID: 27082504)
1. SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants.
Matic M; de Wildt SN; Elens L; de Hoon JN; Annaert P; Tibboel D; van Schaik RH; Allegaert K
Ther Drug Monit; 2016 Aug; 38(4):487-92. PubMed ID: 27082504
[TBL] [Abstract][Full Text] [Related]
2. Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption.
Stamer UM; Musshoff F; Stüber F; Brockmöller J; Steffens M; Tzvetkov MV
Pain; 2016 Nov; 157(11):2467-2475. PubMed ID: 27541716
[TBL] [Abstract][Full Text] [Related]
3. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol.
Tzvetkov MV; Saadatmand AR; Lötsch J; Tegeder I; Stingl JC; Brockmöller J
Clin Pharmacol Ther; 2011 Jul; 90(1):143-50. PubMed ID: 21562485
[TBL] [Abstract][Full Text] [Related]
4. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
5. Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants.
Allegaert K; van Schaik RH; Vermeersch S; Verbesselt R; Cossey V; Vanhole C; van Fessem M; de Hoon J; van den Anker JN
Pediatr Res; 2008 Jun; 63(6):674-9. PubMed ID: 18317231
[TBL] [Abstract][Full Text] [Related]
6. Covariates of tramadol disposition in the first months of life.
Allegaert K; van den Anker JN; de Hoon JN; van Schaik RH; Debeer A; Tibboel D; Naulaers G; Anderson BJ
Br J Anaesth; 2008 Apr; 100(4):525-32. PubMed ID: 18303070
[TBL] [Abstract][Full Text] [Related]
7. OCT1 pharmacogenetics in pain management: is a clinical application within reach?
Tzvetkov MV
Pharmacogenomics; 2017 Nov; 18(16):1515-1523. PubMed ID: 29061087
[TBL] [Abstract][Full Text] [Related]
8. O-demethylation of tramadol in the first months of life.
Allegaert K; Van den Anker JN; Verbesselt R; de Hoon J; Vanhole C; Tibboel D; Devlieger H
Eur J Clin Pharmacol; 2005 Dec; 61(11):837-42. PubMed ID: 16283273
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
10. Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study.
Allegaert K; Holford N; Anderson BJ; Holford S; Stuber F; Rochette A; Trocóniz IF; Beier H; de Hoon JN; Pedersen RS; Stamer U
Clin Pharmacokinet; 2015 Feb; 54(2):167-78. PubMed ID: 25258277
[TBL] [Abstract][Full Text] [Related]
11. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity.
Arafa MH; Atteia HH
Toxicol Appl Pharmacol; 2018 May; 346():37-44. PubMed ID: 29555325
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic analysis of tramadol and
Lee J; Yoo HD; Bae JW; Lee S; Shin KH
Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765
[No Abstract] [Full Text] [Related]
14. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity.
Allegaert K; Anderson BJ; Verbesselt R; Debeer A; de Hoon J; Devlieger H; Van Den Anker JN; Tibboel D
Br J Anaesth; 2005 Aug; 95(2):231-9. PubMed ID: 15951326
[TBL] [Abstract][Full Text] [Related]
15. OCT1 identity crisis.
Sreenivasan S; Viljoen CD
Gene; 2013 Mar; 516(1):190-1. PubMed ID: 23266821
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J
Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214
[TBL] [Abstract][Full Text] [Related]
17. Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to Children.
Hahn D; Emoto C; Vinks AA; Fukuda T
Drug Metab Dispos; 2017 Jan; 45(1):23-26. PubMed ID: 27780835
[TBL] [Abstract][Full Text] [Related]
18. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
[TBL] [Abstract][Full Text] [Related]
19. Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.
Neul C; Hofmann U; Schaeffeler E; Winter S; Klein K; Giacomini KM; Eichelbaum M; Schwab M; Nies AT
Br J Pharmacol; 2021 Mar; 178(6):1459-1474. PubMed ID: 33434947
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S
Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
